Coronary Revascularization clinical trials at UCLA
1 research study open to eligible people
Showing trials for
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
open to eligible people ages 18-99
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).
Los Angeles, California and other locations
Last updated: